Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avdoralimab - Innate Pharma

Drug Profile

Avdoralimab - Innate Pharma

Alternative Names: Anti-C5aR-215; IPH-5401; NN-8210; NNC-0215-0384

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Innate Pharma; MedImmune; Novo Nordisk
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pneumonia
  • Phase I Liver cancer; Non-small cell lung cancer; Solid tumours
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 27 Apr 2020 Phase-II clinical trials in Pneumonia in France (IV) (NCT04371367) (EudraCT2020-001686-36)
  • 07 Oct 2019 Innate Pharma plans a phase I/II trial for Solid tumours
  • 01 Oct 2019 Preliminary efficacy, adverse events and pharmacodynamics data from the phase I STELLAR-001 trial in Solid tumours released by Innate Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top